Oct. 31, 2024 — A research team has found that giving iron supplements to children living with human immunodeficiency virus (HIV) in sub-Saharan Africa could be an ... Kidney Transplantation ...
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced ...
Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...
In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic ...
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. ...
testing the drug as either a monotherapy or in combination with the likes of Johnson & Johnson’s approved androgen receptor inhibitor Erleada. With Essa’s remaining two assets—both AR N ...
Growth is being driven by existing products like Darzalex, Tremfya and Erleada and also continued uptake of new launches, including Spravato, Carvykti and Tecvayli. J&J is making rapid progress ...
Wednesday, October 30, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including ...
Growth is being driven by existing products like Darzalex, Tremfya and Erleada and also continued uptake of new launches, including Spravato, Carvykti and Tecvayli. J&J is making rapid progress ...
Independent Online, popularly known as IOL, is one of South Africa’s leading news and information websites bringing millions of readers breaking news and updates on Politics, Current Affairs ...